Temitope Sobodu | arXiv Science

arXiv2026

Exploring Optimal Parameters for Ligand-Based Virtual Screening in Early Drug Discovery

Ligand-based virtual screening depends on choices that are often treated as implementation details, including the similarity threshold, fingerprint setting and atom-invariant scheme. We examined how these choices altered the composition of ranked searches against the Enamine library for four aminergic reference ligands: atomoxetine, bupropion, mirtazapine and venlafaxine. Candidate sets were evaluated by compound-weighted scaffold novelty, normalized Shannon scaffold diversity and three computational estimates of synthetic accessibility. We first identified ligand-specific operating points along cumulative Tanimoto-ranked searches. We then compared five extended-connectivity fingerprint settings at matched retrieval depths and compared ECFP4 with the feature-class analogue FCSFP4. Finally, 240 records, corresponding to 229 unique structures, were scored independently by three chemists who were blinded to the computational scores. No single Tanimoto cutoff described all four searches. ECFP8 provided the most stable pooled setting, although venlafaxine favored ECFP2. ECFP4 was the stronger primary fingerprint in pooled comparisons, whereas FCSFP4 contributed nonredundant chemical space. Agreement among individual chemists was moderate, and the mean rating was more reliable than a single rating. SCScore showed the highest association with the blinded consensus, but performance varied by ligand. These results support a staged screening design in which a pooled default is followed by ligand-specific calibration and expert review.

q-bio.BM↗

arXiv2024

Discrimination vs. Generation: The Machine Learning Dichotomy for Dopaminergic Hit Discovery

Virtual screening plays a pivotal role in early drug discovery, traditionally dominated by physics-based methods. While these approaches offer detailed insights, they are often hindered by high computational costs, limited sampling, and forcefield inaccuracies. Advances in Machine Learning (Ml)and Deep Learning (DL) present resource-efficient alternatives, with approaches like predictive geometric ML (EQUIBIND) and generative geometric ML (DIFFDOCK)showing promise in enhancing both efficiency and predictive capability. Here, we compare these two strategies, retrospectively and prospectively, for identifying novel agonists targeting the dopamine D2 receptor. To complement DIFFDOCK's dual functionality in protein-ligand conformer generation and confidence estimation, we adopted a complementary atom-type-based confidence model for EQUIBIND. This pipeline, termed the discriminative model, integrates a featurization step and an XGBoost classifier to differentiate between active and inactive ligands. The top-ranked compounds from both models were evaluated using an ultrafast dopaminergic biosensor assay, dLight. Our results demonstrate that the generative model achieved a higher hit rate, notably leading to the discovery of Compound 1, a nanomolar dopamine D2 receptor agonist with a novel scaffold.

q-bio.BM↗